Privia Health Group, Inc. (PRVA)
NASDAQ: PRVA · Real-Time Price · USD
20.07
-0.06 (-0.30%)
Dec 20, 2024, 4:00 PM EST - Market closed
Privia Health Group Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Privia Health Group stock have an average target of 24.46, with a low estimate of 20 and a high estimate of 28. The average target predicts an increase of 21.87% from the current stock price of 20.07.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PRVA stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 6 | 6 | 7 | 7 | 7 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Macquarie | Macquarie | Buy Initiates $25 | Buy | Initiates | $25 | +24.56% | Dec 16, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $27 → $28 | Buy | Maintains | $27 → $28 | +39.51% | Nov 29, 2024 |
| Barclays | Barclays | Hold Maintains $19 → $21 | Hold | Maintains | $19 → $21 | +4.63% | Nov 8, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $24 → $27 | Strong Buy | Maintains | $24 → $27 | +34.53% | Nov 8, 2024 |
| Keybanc | Keybanc | Buy Initiates $23 | Buy | Initiates | $23 | +14.60% | Oct 11, 2024 |
Financial Forecast
Revenue This Year
2.96B
from 1.66B
Increased by 78.44%
Revenue Next Year
3.30B
from 2.96B
Increased by 11.43%
EPS This Year
0.13
from 0.19
Decreased by -29.25%
EPS Next Year
0.26
from 0.13
Increased by 95.11%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3.1B | 3.5B | 4.2B | |||
| Avg | 3.0B | 3.3B | 3.7B | |||
| Low | 2.8B | 3.1B | 3.3B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 89.5% | 19.6% | 26.7% | |||
| Avg | 78.4% | 11.4% | 12.0% | |||
| Low | 69.5% | 4.3% | 1.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.20 | 0.36 | 0.53 |
| Avg | 0.13 | 0.26 | 0.36 |
| Low | 0.11 | 0.19 | 0.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 5.0% | 165.6% | 100.2% |
| Avg | -29.2% | 95.1% | 38.8% |
| Low | -43.3% | 38.5% | -2.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.